Replies to post #141525 on Biotech Values

[mcbio]

That certainly is a compound of interest as well, just that it is early on as you state.

I never followed the stock action of Galopogos. Do you rate it a buy here?

I don't have a position in Galapagos right now but have them high up on my watchlist. The option ABT took on their JAK was impressive and market cap remains just around $400M. That said, I posted one concern on ABT as their partner in #msg-74568805 (ABT has their own JAK-1 inhibitor at pre-clinical stage).